Comparing the current results to its competitors, Aldeyra Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 38.38 %, recorded in the same quarter.
July 17, 2025
Aldeyra Therapeutics Advances Towards FDA Approval for Reproxalap: A Potential Breakthrough in the Treatment of Dry Eye Disease LEXINGTON, Mass. Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a pioneering biotechnology firm dedicated to developing innovative therapies for immune-mediated and metabolic disorders, is making strides in the treatment of dry eye disease with the recent acceptance of the resubmitted New Drug Application (NDA) for reproxalap by the U.S. Food and Drug Administration (FDA). This milestone, combined with successful trial results, marks a significant step forward in addressing an unmet medical need for millions suffering from this chronic condition.The FDA s acceptance of the NDA signa...
May 9, 2025
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has recently found itself in a tumultuous position as investors express concern over the biotech company s stock fluctuations and potential legal issues. Amidst a mixture of promising advancements in clinical trials and unsettling stock performance, the company is attracting both scrutiny and attention from legal firms.On May 5, 2025, Aldeyra achieved a significant milestone by successfully meeting the primary endpoint in its Phase 3 clinical trial for Reproxalap, a treatment for dry eye disease. This news had the potential to bolster investor confidence as Aldeyra plans to resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration. Such progres...
May 8, 2024
Aldeyra Therapeutics Advances Reproxalap as a Potential Breakthrough Treatment for Dry Eye Disease with Enrollment of First Patient in Phase 3 Clinical TrialLEXINGTON, Mass. - Aldeyra Therapeutics, a pioneering biotechnology company specializing in the development of innovative therapies for immune-mediated and metabolic diseases, made a significant stride today with the enrollment of the first patient in a Phase 3 clinical trial for the investigational drug reproxalap. The study aims to enable a potential resubmission of the New Drug Application (NDA) for the treatment of dry eye disease, a condition affecting millions worldwide.Dry eye disease, characterized by inadequate tear production or poor quality te...
April 25, 2024
Aldeyra Therapeutics, a leading biotechnology company, recently presented noteworthy updates on their research and development pipeline at the Aldeyra 2024 Research and Development Day in New York City. The event provided a platform to share the latest findings on their RASP modulation platform and ADX-2191, focusing on its potential applications for retinitis pigmentosa. Additionally, preclinical data was revealed for investigational RASP modulators targeting obesity, atopic dermatitis, inflammatory pain, and alcoholic hepatitis. In this article, we will outline the facts and assess the impact of these developments on Aldeyra Therapeutics.1. Expansion of the RASP Modulation Platform:At RandD Day, Aldeyra Th...
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Iris Energy Ltd is a company that specializes in developing and operating cryptocurrency mining facilities, primarily focusing on Bitcoin mining. They generate revenue by utilizing their mining infrastructure to validate and process cryptocurrency transactions, earning rewards in the form of newly minted digital coins.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Sources:
Aldeyra Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aldeyra Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
